If analyzed over time, the incidence (percent of subjects affected per injection period) of flu-like symptoms showed an increase from 21% (1st injection period) to 44% (2nd) and thereafter declined to 40% (3rd), 25% (4th) and 24% (5th injection period). injection. Point prevalence of abstinence at month 2 showed a statistically significant difference between subjects treated with Nicotine-Q (47.2%) and placebo (35.1%) (when whatsoever monthly appointments from month 3 until month 6 they declared themselves as being nonsmokers during that period and when the carbon monoxide concentration in their exhaled air flow was below 10 ppm. We did not use cotinine as a second confirmation means of abstinence because the binding of nicotine to antibodies might prolong the removal of nicotine and its metabolite cotinine [17]. of smoking or of abstinence was defined at each assessment visit as the smoking status (self-report confirmed by CO below 10 ppm) of a study participant at that check out, irrespective of his/her smoking status within the appointments before or after. Self-reported cigarette usage was recorded daily in paper and pencil diaries. Subjects with missing appointments or who were lost to follow-up at any time during the study were considered as smokers. Given the exploratory nature of this Phase II trial, the study protocol stipulated that additional evaluations guided from the results might be regarded as, in particular the correlation between the clinical end result and anti-nicotine antibody titers could be assessed. The other main results were immunogenicity, security and tolerability of Nicotine-Q. The immunogenicity was assessed by dedication of specific anti-nicotine antibodies of IgG isotype by ELISA using an RNAse-nicotine conjugate [9] in sera before vaccination and then at regular monthly intervals up to month 6 and at HS-173 weeks 9 and 12. Since a human being anti-nicotine monoclonal IgG research standard was not available, nicotine-specific IgG levels are reported as titers. The ELISA titer for each serum specimen corresponds to the dilution needed to accomplish an optical denseness of 50% of the optical denseness reached at saturation. An antibody responder was defined as a subject who experienced an anti-nicotine IgG titer, which was larger than the unspecific background reactivity (average plus three standard deviations) of the ELISA. Background reactivity of the ELISA was HS-173 identified using preimmune sera. Sub-group analyses were performed by using the area under the curve (AUC) of log-transformed titers from month 3 to month 6. Security and tolerability were assessed through systematic collection of vital indicators and all reported symptoms, as well as standard clinical laboratory and injection site examination in all subjects. A specific security check-up was performed one week after each injection. Subjects also kept a diary for self-assessment of local reactions. Info was collected about adverse events that occurred during the double blind and follow-up periods. An adverse event was any fresh undesirable medical event, which did not necessarily have to have a causal relationship with this treatment. The classification of the severity was based on the following level. was any untoward medical event that at any dose resulted in death, in persisting or significant disability/incapacity, was HS-173 life-threatening, required in-patient hospitalization, or any significant medical event mainly because judged from the investigators. To assess craving and withdrawals symptoms, we used two questionnaires, the Questionnaire on Smoking Urges [18] dealing with two conditions (i.e., intention Rabbit Polyclonal to eNOS to smoke and anticipation of relief from the urgent desire to smoke) and the Wisconsin Withdrawal Scale [19] dealing with craving, concentration, sleeplessness, anger, panic, sadness and hunger. Statistical analyses Statistical analyses were performed with SAS for Microsoft Windows? 9.1.3. Pearson Chi-Square test without correction was used to calculate the statistical significance of the effect of vaccination (active versus placebo) and the effect of antibody titer levels (high, medium, low versus placebo) on continuous abstinence and on point prevalence abstinence. For continuous variables variations between two organizations were analyzed with the two-sample t-test or with the Mann-Whitney test as nonparametric test, and, for more than two organizations, with analysis of variance or the Kruskal-Wallis test as nonparametric test. The influence of baseline guidelines within the abstinence rate was tested by means of a logistic regression analysis (SAS ProcLogistic using the binary logit model). Results were regarded as significant if p ideals of the respective statistical tests were smaller than 0.05. Smoking replacement users were excluded from your per-protocol analysis. We powered our study on rates of continuous abstinence and determined a sample size that would detect a difference of at least 15% (smoking abstinence.